These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 30404440)
21. Oestrogen receptors pathways to oestrogen responsive elements: the transactivation function-1 acts as the keystone of oestrogen receptor (ER)beta-mediated transcriptional repression of ERalpha. Gougelet A; Mueller SO; Korach KS; Renoir JM J Steroid Biochem Mol Biol; 2007 May; 104(3-5):110-22. PubMed ID: 17478088 [TBL] [Abstract][Full Text] [Related]
22. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351. MacGregor Schafer J; Liu H; Bentrem DJ; Zapf JW; Jordan VC Cancer Res; 2000 Sep; 60(18):5097-105. PubMed ID: 11016635 [TBL] [Abstract][Full Text] [Related]
23. Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα Puyang X; Furman C; Zheng GZ; Wu ZJ; Banka D; Aithal K; Agoulnik S; Bolduc DM; Buonamici S; Caleb B; Das S; Eckley S; Fekkes P; Hao MH; Hart A; Houtman R; Irwin S; Joshi JJ; Karr C; Kim A; Kumar N; Kumar P; Kuznetsov G; Lai WG; Larsen N; Mackenzie C; Martin LA; Melchers D; Moriarty A; Nguyen TV; Norris J; O'Shea M; Pancholi S; Prajapati S; Rajagopalan S; Reynolds DJ; Rimkunas V; Rioux N; Ribas R; Siu A; Sivakumar S; Subramanian V; Thomas M; Vaillancourt FH; Wang J; Wardell S; Wick MJ; Yao S; Yu L; Warmuth M; Smith PG; Zhu P; Korpal M Cancer Discov; 2018 Sep; 8(9):1176-1193. PubMed ID: 29991605 [TBL] [Abstract][Full Text] [Related]
24. Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion. JavanMoghadam S; Weihua Z; Hunt KK; Keyomarsi K Cell Cycle; 2016 Jun; 15(12):1579-90. PubMed ID: 27049344 [TBL] [Abstract][Full Text] [Related]
25. Novel class of 7-Oxabicyclo[2.2.1]heptene sulfonamides with long alkyl chains displaying improved estrogen receptor α degradation activity. Hu Z; Li Y; Xie B; Ning W; Xiao Y; Huang Y; Zhao C; Huang J; Dong C; Zhou HB Eur J Med Chem; 2019 Nov; 182():111605. PubMed ID: 31437778 [TBL] [Abstract][Full Text] [Related]
26. Development of the β-lactam type molecular scaffold for selective estrogen receptor α modulator action: synthesis and cytotoxic effects in MCF-7 breast cancer cells. Carr M; Knox AJ; Lloyd DG; Zisterer DM; Meegan MJ J Enzyme Inhib Med Chem; 2016; 31(sup3):117-130. PubMed ID: 27476825 [TBL] [Abstract][Full Text] [Related]
27. Cooperative coactivation of estrogen receptor alpha in ZR-75 human breast cancer cells by SNURF and TATA-binding protein. Saville B; Poukka H; Wormke M; Janne OA; Palvimo JJ; Stoner M; Samudio I; Safe S J Biol Chem; 2002 Jan; 277(4):2485-97. PubMed ID: 11696545 [TBL] [Abstract][Full Text] [Related]
28. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448 [No Abstract] [Full Text] [Related]
29. Estrogen receptor-alpha-interacting cytokeratins potentiate the antiestrogenic activity of fulvestrant. Long X; Fan M; Nephew KP Cancer Biol Ther; 2010 Mar; 9(5):389-96. PubMed ID: 20061804 [TBL] [Abstract][Full Text] [Related]
30. Differential response of estrogen receptor subtypes to 1,3-diarylindene and 2,3-diarylindene ligands. Clegg NJ; Paruthiyil S; Leitman DC; Scanlan TS J Med Chem; 2005 Sep; 48(19):5989-6003. PubMed ID: 16162002 [TBL] [Abstract][Full Text] [Related]
31. Phenytoin is an estrogen receptor α-selective modulator that interacts with helix 12. Fadiel A; Song J; Tivon D; Hamza A; Cardozo T; Naftolin F Reprod Sci; 2015 Feb; 22(2):146-55. PubMed ID: 25258361 [TBL] [Abstract][Full Text] [Related]
32. Development of 2,3,5-triaryl-1H-pyrroles as estrogen receptor α selective ligands. Schäfer A; Wellner A; Strauss M; Wolber G; Gust R ChemMedChem; 2011 Nov; 6(11):2055-62. PubMed ID: 21990277 [TBL] [Abstract][Full Text] [Related]
33. Elucidating Binding Sites and Affinities of ERα Agonists and Antagonists to Human Alpha-Fetoprotein by In Silico Modeling and Point Mutagenesis. Moldogazieva NT; Ostroverkhova DS; Kuzmich NN; Kadochnikov VV; Terentiev AA; Porozov YB Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019136 [TBL] [Abstract][Full Text] [Related]
34. Structure-activity relationship study of estrogen receptor down-regulators with a diphenylmethane skeleton. Nanjyo S; Ohgane K; Yoshioka H; Makishima M; Hashimoto Y; Noguchi-Yachide T Bioorg Med Chem; 2019 May; 27(10):1952-1961. PubMed ID: 30940565 [TBL] [Abstract][Full Text] [Related]
35. Domains of estrogen receptor alpha (ERalpha) required for ERalpha/Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in breast cancer cells. Kim K; Thu N; Saville B; Safe S Mol Endocrinol; 2003 May; 17(5):804-17. PubMed ID: 12576490 [TBL] [Abstract][Full Text] [Related]
36. Molecular mechanisms of selective estrogen receptor modulator activity in human breast cancer cells: identification of novel nuclear cofactors of antiestrogen-ERα complexes by interaction proteomics. Cirillo F; Nassa G; Tarallo R; Stellato C; De Filippo MR; Ambrosino C; Baumann M; Nyman TA; Weisz A J Proteome Res; 2013 Jan; 12(1):421-31. PubMed ID: 23170835 [TBL] [Abstract][Full Text] [Related]
37. Discovery of novel natural compound inhibitors targeting estrogen receptor α by an integrated virtual screening strategy. Yu E; Xu Y; Shi Y; Yu Q; Liu J; Xu L J Mol Model; 2019 Aug; 25(9):278. PubMed ID: 31463793 [TBL] [Abstract][Full Text] [Related]
38. Synthesis of novel estrogen receptor antagonists using metal-catalyzed coupling reactions and characterization of their biological activity. Jiang XR; Wang P; Smith CL; Zhu BT J Med Chem; 2013 Apr; 56(7):2779-90. PubMed ID: 23448346 [TBL] [Abstract][Full Text] [Related]
39. AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models. Weir HM; Bradbury RH; Lawson M; Rabow AA; Buttar D; Callis RJ; Curwen JO; de Almeida C; Ballard P; Hulse M; Donald CS; Feron LJ; Karoutchi G; MacFaul P; Moss T; Norman RA; Pearson SE; Tonge M; Davies G; Walker GE; Wilson Z; Rowlinson R; Powell S; Sadler C; Richmond G; Ladd B; Pazolli E; Mazzola AM; D'Cruz C; De Savi C Cancer Res; 2016 Jun; 76(11):3307-18. PubMed ID: 27020862 [TBL] [Abstract][Full Text] [Related]
40. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models. Bahreini A; Li Z; Wang P; Levine KM; Tasdemir N; Cao L; Weir HM; Puhalla SL; Davidson NE; Stern AM; Chu D; Park BH; Lee AV; Oesterreich S Breast Cancer Res; 2017 May; 19(1):60. PubMed ID: 28535794 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]